IBM’s Quantum Bet Offers a Lifeline as Infrastructure Woes Deepen
Published on 07/25/2026 at 11:41 | Redaktion boerse-global.de
The numbers out of Armonk this week tell two sharply different stories. One is about a legacy hardware business in retreat, where mainframe sales have cratered and customers are hoarding their budgets. The other is about a long-shot wager on quantum computing that could reshape the company — if the market gives management enough time to see it through.
IBM reported second-quarter revenue of $17.16 billion on Thursday, falling short of the $17.46 billion analysts had expected. Earnings per share came in at $2.93, matching the consensus but missing Bernstein’s more optimistic $3.01 estimate. The company trimmed its full-year constant-currency revenue growth forecast to a range of 4% to 5%, down from the previous guidance of more than 5%.
The culprit was the infrastructure division, where sales slid 7% and mainframe revenue collapsed 42%. Clients facing tight investment budgets have pushed back large orders, a dynamic that also weighed on the transaction processing business. The pain was partially offset by software, which grew 5%, and the distributed infrastructure unit, which posted a record quarter with a 37% revenue jump and a backlog of roughly $500 million. Consulting contract signings rose 6%, with generative AI now accounting for half of all new deals. Annual recurring revenue climbed 8% to $24.6 billion, and free cash flow reached $4.8 billion in the first half, with management targeting a $1 billion year-over-year increase for the full year. The quarterly dividend held steady at $1.69 per share.
A Quantum Pivot at a Precarious Moment
On the same day as the earnings release, IBM confirmed it has reached a definitive agreement to acquire HRL Laboratories, a research institute founded in 1948 as Hughes Research Laboratories and currently co-owned by Boeing and General Motors. Financial terms were not disclosed, and the deal is expected to close by the end of the third quarter. HRL specializes in silicon-spin qubits, a technology that IBM plans to integrate with its existing superconducting quantum chip program. Jay Gambetta, IBM’s director of research, said the HRL team will help accelerate innovation in the quantum space, while HRL CEO Rob Vasquez described joining IBM as a natural next step.
Should investors sell immediately? Or is it worth buying IBM?
The acquisition fits into a roadmap that calls for more than $10 billion in quantum-related spending over the next five years. By 2029, IBM aims to deliver “Quantum Starling,” a fault-tolerant quantum computer capable of roughly 100 million quantum operations, followed by “Blue Jay,” a successor system targeting one billion operations. The company also announced “Anderon,” which it bills as the first dedicated quantum wafer fabrication facility in the U.S., a project that is expected to receive government support.
The strategic logic is clear: control the physical manufacturing chain rather than just the software layer, and you build a structural moat. IBM’s ambition, as some observers have framed it, is to become the TSMC of quantum technology. But that transformation comes at a cost — and the company’s risk profile is shifting accordingly. The annualized 30-day volatility now stands at 84.97%, a level more typical of high-growth speculative names than of a blue-chip stalwart.
A Stock Caught Between Fear and Hope
The market’s reaction to the mixed news was telling. Shares rose 3.74% on Friday to €188.38, and options trading volume ran about a third above the daily average. Yet that bounce does little to change the year-to-date picture: IBM stock is still down 27.52% in 2026, and the current price sits 17.61% below its 50-day moving average of €228.64.
The recent volatility has been extreme. On July 14, the stock suffered its worst single-day loss in modern history, plunging more than 25% after a preliminary earnings release showed just 1% revenue growth. CEO Arvind Krishna attributed the miss to a late shift in customer spending, as clients redirected budgets from high-margin software and consulting toward AI-ready infrastructure. The wounds from that session are still fresh. Just two days before Friday’s rebound, the stock touched a 52-week low of €175.14, amid reports of an investigation into potential securities fraud related to pipeline transparency.
IBM at a turning point? This analysis reveals what investors need to know now.
Analysts remain divided. Bernstein cut its price target from $280 to $230 and downgraded the stock to Market Perform, citing delays in mainframe and transaction processing orders. The firm now sees full-year EPS of $12.23, rising to $13.40 in 2027. Citigroup maintained its Buy rating with a $245 target. The broader consensus sits at Moderate Buy, with an average price target of $265.40 — implying roughly 22.7% upside from Friday’s close. The 14-day relative strength index of 35.5 suggests the stock is approaching oversold territory, leaving technical room for a recovery.
The fundamental question, however, is whether IBM can prove that its hardware transformation will eventually outweigh the drag from its legacy software business. The HRL acquisition and the Anderon fab represent a massive bet on a future that is still years away from generating meaningful revenue. For now, the market is left to weigh a 42% mainframe collapse against the promise of a quantum revolution — and to decide whether the company’s long-term wager is worth the short-term pain.
Ad
IBM Stock: New Analysis - 25 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
